Voyager Therapeutics

VYGR · Nasdaq · United States

Share price · VYGR

$1.67-1.63 (-49.39%) 3M

close as of 2026-11-18 · 24h delayed · vol 840K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VYGR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+9.9%
  2. 10 Nov 2026-8.3%
  3. 22 Oct 2026-7.9%
  4. 21 Oct 2026-7.8%
  5. 19 Oct 2026+7.9%

    Nothing announced by VYGR that day or the session before.

  6. 14 Oct 2026-6.5%
  7. 12 Oct 2026-7.3%

    Nothing announced by VYGR that day or the session before.

  8. 2 Oct 2026-8.4%

    Nothing announced by VYGR that day or the session before.

  9. 23 Sep 2026-8.6%
  10. 17 Mar 2026-9.3%

Share of unusual movement by asset

For each asset, the share of VYGR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—80%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Tau (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$4.0M$24M$51M+ $58M short-term inv.$25M-$20M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.2M$22M$39M+ $81M short-term inv.$24M-$26M operating cash flowreport ↗
2026-Q1$2.6M$25M$46M+ $98M short-term inv.$28M-$33M operating cash flowreport ↗
2025-Q3$13M$36M$51M+ $164M short-term inv.$28M-$31M operating cash flowreport ↗
2025-Q2$5.2M$31M$47M+ $172M short-term inv.$33M-$33M operating cash flowreport ↗
2025-Q1$6.5M$32M$78M+ $161M short-term inv.$31M-$38M operating cash flowreport ↗
2024-Q3$25M$30M$115M+ $233M short-term inv.$9.0M-$28M operating cash flowreport ↗
2024-Q2$30M$34M$79M+ $295M short-term inv.$10M-$32M operating cash flowreport ↗
2024-Q1$20M$27M$146M+ $256M short-term inv.$11M$59M operating cash flowreport ↗
2023-Q3$4.6M$26M$67M+ $188M short-term inv.$26M-$21M operating cash flowreport ↗
2023-Q2$4.8M$22M$246M+ $28M short-term inv.$22M-$0.8M operating cash flowreport ↗
2023-Q1$150M$19M$270M+ $5.0M short-term inv.—$124M operating cash flowreport ↗
2022-Q3$41M$19M$98M+ $35M short-term inv.—-$16M operating cash flowreport ↗
2022-Q2$0.7M$13M$80M+ $70M short-term inv.$19M-$18M operating cash flowreport ↗
2022-Q1$0.7M$14M$134M+ $35M short-term inv.$21M$34M operating cash flowreport ↗
2021-Q3$1.5M$18M$113M+ $10M short-term inv.$25M-$21M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$40M$135M$68M+ $131M short-term inv.$30M-$132M operating cash flowreport ↗

Voyager Therapeutics reported full-year 2025 collaboration revenue of $40.4M, down 49.5% YoY from $80.0M, while R&D spend was $134.7M, up 5.7% YoY from $127.4M. The company ended 2025 with a cash position of $201.7M in cash, cash equivalents, and marketable securities, and reported a net loss of $119.7M versus $65.0M in the prior year. No analyst consensus comparison was provided in the materials.

For 2026, Voyager expects its cash runway to extend into 2028, with potential additional non-dilutive milestone payments of up to $2.4B. Pipeline expectations include VY1706 IND submission in Q2 2026 and first-in-human dosing in H2 2026, tau PET imaging data from the VY7523 MAD trial in H2 2026, and Neurocrine’s planned initiation of a clinical trial for NBIB-223 in Friedreich’s ataxia in H2 2026 pending FDA clearance. The company also highlighted a Voyager NeuroShuttle proof-of-concept study supporting sustained brain exposure and noted that its APOE gene therapy program was paused to prioritize more advanced programs.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$80M$127M$74M+ $195M short-term inv.$16M-$15M operating cash flowreport ↗
2023-FY$250M$92M$70M+ $162M short-term inv.—$78M operating cash flowreport ↗
2022-FY$41M$61M$100M+ $20M short-term inv.$12M-$13M operating cash flowreport ↗
2021-FY$37M$74M$119M+ $15M short-term inv.$18M-$54M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($298K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-01Swartz Robin · PresidentAward / grant68,250——Form 4
2026-11-01Carter Todd Alfred · Chief Scientific OfficerAward / grant33,000——Form 4
2026-11-01Swartz Robin · PresidentAward / grant (derivative)318,500——Form 4
2026-11-01Carter Todd Alfred · Chief Scientific OfficerAward / grant (derivative)154,000——Form 4
2026-06-09PIERCE GLENN · directorAward / grant (derivative)30,000——Form 4
2026-06-09Colon Grace · directorAward / grant (derivative)30,000——Form 4
2026-06-09GERAGHTY JAMES A · directorAward / grant (derivative)30,000——Form 4
2026-06-09Onyia Jude · directorAward / grant (derivative)30,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 134 reporting institutions held 33.5M shares ($127.5M, 53.9% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.5,568,381$21.5M
2ARMISTICE CAPITAL, LLC3,500,000$13.5M
3MILLENNIUM MANAGEMENT LLC3,428,571$13.2M
4Vestal Point Capital, LP3,002,936$11.6M
5VANGUARD CAPITAL MANAGEMENT LLC2,283,253$8.8M
6Opaleye Management Inc.1,150,000$4.4M
7Erste Asset Management GmbH1,095,141$4.2M
8GEODE CAPITAL MANAGEMENT, LLC1,049,978$4.1M
9STATE STREET CORP948,226$3.7M
10DIMENSIONAL FUND ADVISORS LP875,568$3.4M
11VANGUARD PORTFOLIO MANAGEMENT LLC725,769$2.8M
12MORGAN STANLEY681,711$2.6M
13TWO SIGMA INVESTMENTS, LP615,660$2.4M
14RENAISSANCE TECHNOLOGIES LLC578,024$2.2M
15SPHERA FUNDS MANAGEMENT LTD.469,761$1.8M